Loading...

Follow Palm Beach Neurological Center on Feedspot

Continue with Google
Continue with Facebook
or

Valid

Palm Beach Neurological Center is participating in a clinical trial to examine if an investigational drug may help slow or stop memory loss in people with early stages of Alzheimer’s disease. It is an “Investigational” drug, meaning it has not yet been approved by regulatory authorities for doctors to prescribe in their everyday practice.

Benefits of the Trailblazer-ALZ Study:

As we age,

The post Trailblazer-ALZ Trial… Now Enrolling appeared first on Palm Beach Neurological Center.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Middle aged individuals in their 40s and 50s who have biomarkers linked to inflammation in their blood may have more brain shrinkage years later than individuals without these biomarkers, according to a study published in an article published in an issue of the medical journal Neurology® and the American Academy of Neurology.

The post Middle Age Inflammation Biomarkers may increase Brain Shrinkage appeared first on Palm Beach Neurological Center.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 
Description

Palm Beach Neurological Center is participating in a clinical research study to evaluate an investigational drug called “Delphia” for patients suffering from Dementia with Lewy Bodies. An investigational drug is not yet approved for use by the public. Doctors perform these studies to make sure it is safe and to see if it is helpful for patients with Dementia with Lewy Bodies.

The post Delphia Study for Dementia with Lewy Bodies (DLB)…Enrolling appeared first on Palm Beach Neurological Center.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

The nosology and treatment options for cognitive impairment in Parkinson disease (PD) remains perhaps the greatest unmet clinical need.1 The reported frequency of mild cognitive impairment (MCI) in newly diagnosed PD has ranged from 22% to 43%.2,3 A proportion of those with PD-MCI progress to PD dementia (PDD), the prevalence of which is variously estimated between 24% and 31%,

The post Rethinking cognition in Parkinson disease – Phosphodiesterase 4 appeared first on Palm Beach Neurological Center.

Read Full Article
  • Show original
  • .
  • Share
  • .
  • Favorite
  • .
  • Email
  • .
  • Add Tags 

Separate tags by commas
To access this feature, please upgrade your account.
Start your free month
Free Preview